Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at TD Cowen

Equities researchers at TD Cowen assumed coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a report released on Tuesday, Briefing.com reports. The brokerage set a “buy” rating on the stock.

Separately, Stifel Nicolaus initiated coverage on Bicara Therapeutics in a report on Tuesday. They issued a “buy” rating and a $47.00 price objective for the company.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock opened at $24.45 on Tuesday. Bicara Therapeutics has a one year low of $21.05 and a one year high of $27.94.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the stock in a transaction on Monday, September 16th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the transaction, the director now owns 4,303,418 shares in the company, valued at approximately $77,461,524. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, major shareholder James E. Flynn acquired 70,000 shares of Bicara Therapeutics stock in a transaction that occurred on Tuesday, September 17th. The stock was purchased at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the transaction, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 1,833,000 shares of Bicara Therapeutics stock in a transaction dated Monday, September 16th. The shares were purchased at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the completion of the acquisition, the director now owns 4,303,418 shares in the company, valued at $77,461,524. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.